Stocktoria
TriSalus Life Sciences, Inc. TLSI
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2020-12-18
TriSalus Life Sciences, Inc. statistics & valuation
Market cap$290.5M
P / S6.4×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 84.6% | 86.1% | 85.9% | 81.8% | — |
| Operating margin | -59.7% | -122.9% | -294.3% | -293.9% | — |
| Net margin | -86.9% | -102.1% | -320.7% | -380.6% | — |
| FCF margin | -41.9% | -139.9% | -276.4% | -265.9% | — |
| Return on assets | -111.0% | -125.3% | -241.3% | -214.5% | 1.9% |
| Return on equity | 115.8% | 116.0% | 219.3% | 26.6% | -3.7% |
| Debt / equity | -0.98× | -0.85× | -0.00× | — | — |
| Current ratio | 2.80 | 2.02 | 1.42 | 0.53 | 0.33 |
| Revenue growth | 53.4% | 59.0% | 49.3% | — | — |
Source: SEC EDGAR filings · CIK 0001826667 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.